InflammX Therapeutics-preview

Ocunexus

InflammX Therapeutics

Private

Tampa, FloridaHealthcare & Life Scienceshttps://inflammx.com/

Last Round

Series A

Jan 10, 2025

Total Funding Raised

$67.95M

Momentum Score

50 /100

Company Overview

InflammX Therapeutics is a clinical-stage biopharmaceutical company developing Xiflam, an orally administered small molecule to treat retinal diseases such as the dry form of age-related macular degeneration (AMD).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

oral AMD treatmentNLRP3 inflammasomeretinal disease therapyage-related macular degenerationAMDsmall molecule druginflammasome inhibitorConnexin43 inhibitorclinical-stage biotechdry AMDdiabetic retinal diseaseophthalmologydiabetic retinopathyDRdiabetic macular edemaDME

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InflammX Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

InflammX Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jan 10, 2025
Series B	Jul 24, 2012
Series A	Sep 25, 2008

View all Funding Rounds

Key People

Founding team and executive leadership

David Pool

Chief Financial Officer

Executive Team

InflammX Therapeutics Investors

Notable investors and investment history

Investor	Rounds
RusnanoMedInvest	Series B
Domain Associates	Series B, Series A
GBS Venture Partners	Series B, Series A
BioPacificVentures	Series A, Series B
ExSight Ventures	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 22, 2026
Monthly visitors increased 375% MoM to 1.3K.
Feb 1, 2026
Monthly visitors increased 175% MoM.

View all signals

InflammX Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

InflammX Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about InflammX Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTampa, Florida

Employee Range3

Year Founded2005

Last FundingJan 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.